Navigation Links
WallSt.net Announces Upcoming Interview with CSO and COO of Urigen Pharmaceuticals
Date:11/26/2007

NEW YORK, Nov. 26 /PRNewswire/ -- Dr. Dennis Giesing, Chief Scientific Officer and Terry Nida, Chief Operating Officer of Urigen Pharmaceuticals, Inc. (OTC Bulletin Board: URGP) (http://www.urigen.com) will be featured in an exclusive interview with http://www.wallst.net scheduled for November 27 at 10:30 a.m. EST. The interview will be posted on http://www.wallst.net by 8 p.m. EST on November 27.

The interview will cover topics including Urigen Pharmaceutical's market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window.

About Urigen Pharmaceuticals:

Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101 project targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. Urigen's URG301 project targets acute urgency in patients diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency.

For further information, please visit Urigen's website at http://www.urigen.com.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Website is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, Financial Filings Corp., a provider of compliance solutions to publicly traded companies, and WallStRadio, a business and finance podcast Website. Financial Filings Corp. is expecting to receive two hundred eighty dollars from Urigen Pharmaceuticals, Inc. for the dissemination of this press release. For a complete list of our advertisers and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.


'/>"/>
SOURCE Financial Filings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WallSt.net Updates Investment Community Through All-New Interview With Ingen Technologies
2. WallSt.net Updates Investment Community Through All-New Interview With XTend Medical
3. WallSt.net (www.wallst.net) Updates the Investment Community Through All-New Interviews With XMDC, POSS and TYPE
4. Skystar Bio-Pharmaceutical Announces Upcoming Interview With WallSt.net ( www.wallst.net )
5. WallSt.net Announces Upcoming Interview With CEO of Alliance HealthCard
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering local frontline ... field of pain management. , The demand for supplemental training related to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in ... fits into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started ... how the details line up exactly with Bible Prophecy – a protected way for ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
(Date:12/2/2016)...  Today, Simpson Healthcare Executives, a global leader in ... as winners of multiple awards at the 2016 MarCom ... PLATINUM level, Blue Zones Menu at the GOLD Level, ... and our proprietary 3ConneX Platform at the HONORABLE MENTION ... are excited to showcase our new Platinum and Gold ...
(Date:12/2/2016)... 2016 The iShares Nasdaq Biotechnology Exchange-Traded ... Trump,s victory early in November. Less political risk has ... now predicting an uptick in M&A activities. Today, Stock-Callers.com ... how they have fared at the last close: Celldex ... Inc. (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. ...
Breaking Medicine Technology: